QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global leader of innovative in vitro diagnostics, announces it has completed the acquisition of LEX Diagnostics (“LEX”) for cash consideration of approximately $100 million. The LEX VELO System received U.S. Food and Drug Administration (“FDA”) 510(k) clearance and CLIA waiver in February 2026. The LEX VELO System is a breakthrough molecular diagnostics platform that is designed to deliver highly sensitive, multiplex RT-PCR testing for Influenza A, Influenza B and COVID-19 directly from a swab sample in approximately six to ten minutes.
Read the full article: QuidelOrtho Corporation Completes Acquisition of LEX Diagnostics //
Source: https://www.prnewswire.com/news-releases/quidelortho-corporation-completes-acquisition-of-lex-diagnostics-302746364.html